Inflammatory Markers in Substance Use and Mood Disorders: A Neuroimaging Perspective.

Front Psychiatry

Section of Sensory Science and Metabolism Unit, Division of Intramural Research, Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States.

Published: April 2022

Chronic exposure to addictive drugs in substance use disorders and stressors in mood disorders render the brain more vulnerable to inflammation. Inflammation in the brain, or neuroinflammation, is characterized by gliosis, microglial activation, and sustained release of cytokines, chemokines, and pro-inflammatory factors compromising the permeability of the blood-brain barrier. There is increased curiosity in understanding how substance misuse and/or repeated stress exposure affect inflammation and contribute to abnormal neuronal activity, altered neuroplasticity, and impaired cognitive control, which eventually promote compulsive drug-use behaviors and worsen mood disorders. This review will emphasize human imaging studies to explore the link between brain function and peripheral markers of inflammation in substance use disorders and mood disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086785PMC
http://dx.doi.org/10.3389/fpsyt.2022.863734DOI Listing

Publication Analysis

Top Keywords

mood disorders
16
substance disorders
8
disorders
6
inflammatory markers
4
substance
4
markers substance
4
mood
4
substance mood
4
disorders neuroimaging
4
neuroimaging perspective
4

Similar Publications

Background: Medical history and healthcare utilization in preclinical Alzheimer's disease (AD) are not well characterized and may reveal indicators associated with asymptomatic stages of AD.

Methods: This retrospective observational study compared 246 Anti-Amyloid Treatment in Asymptomatic AD study (A4) individuals who met elevated brain amyloid eligibility criteria to 121 individuals in the companion Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study (LEARN) who were eligible for A4 except did not meet elevated amyloid eligibility criteria. Matched-controls for A4/LEARN, using a 3:1 match of demographics, Medicare enrollment month, and frailty status, were randomly selected from Medicare beneficiaries without cognitive impairment/dementia claims.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.

Background: With the changing care landscape for early Alzheimer's disease (AD), optimizing the diagnostic and management process is key. This study assessed the correlation between patient and physician characteristics and outcomes related to the diagnosis, referral, and treatment process for early AD in community-based settings.

Method: This cross-sectional study conducted between August and September 2023 abstracted medical chart data for patients aged 50-89 years who were diagnosed with early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and had a clinic visit within the past year.

View Article and Find Full Text PDF

Background: Patients with Alzheimer's disease due to the peculiarities of this disease do not report constipation.

Method: In a study of 11 women with Alzheimer's disease, aged 70-75 years, we found that all of them had a tendency towards constipation. We divided the patients into two groups: a control group of 6 women who received help when they complained of constipation symptoms and an experimental group of 5 female patients who were routinely assessed by caregivers on their fecal status using the Bristol Scale.

View Article and Find Full Text PDF

Dementia Care Practice.

Alzheimers Dement

December 2024

Athens Alzheimer Association, Athens, Attica, Greece.

There are 160.000 people living with dementia and 280.000 with Mild Cognitive Impairment (MCI) in Greece.

View Article and Find Full Text PDF

Subtypes of Insomnia Disorder Identified by Cortical Morphometric Similarity Network.

Hum Brain Mapp

January 2025

Sleep and NeuroImaging Center, Faculty of Psychology, Southwest University, Chongqing, China.

Insomnia disorder (ID) is a highly heterogeneous psychiatric disease, and the use of neuroanatomical data to objectively define biological subtypes is essential. We aimed to examine the neuroanatomical subtypes of ID by morphometric similarity network (MSN) and the association between MSN changes and specific transcriptional expression patterns. We recruited 144 IDs and 124 healthy controls (HC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!